HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wilcox, L. J. Articles by Huff, M. W. Search for Related Content PubMed PubMed Citation Articles by Wilcox, L. J. Articles by Huff, M. W. Social Bookmarking                      What's this?

The Journal of Lipid Research, Vol. 40, 1078-1089, June 1999
Copyright © 1999 by Lipid Research, Inc.

Original Article

Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin

Correspondence to: Murray W. Huff

The concept that hepatic cholesterol synthesis regulates hepatocyte assembly and secretion of apoB-containing lipoproteins remains controversial. The present study was carried out in HepG2 cells to examine the regulation of apoB secretion by the HMG-CoA reductase inhibitor atorvastatin. ApoB accumulation in the media was decreased by 24% and 36% at 10 µM (P < 0.02) and 20 µM (P < 0.01) of atorvastatin, respectively. Atorvastatin inhibited HepG2 cell cholesterol synthesis by up to 96% (P < 0.001) and cellular cholesteryl ester (CE) mass by 54% (P < 0.001). Another HMG-CoA reductase inhibitor, simvastatin, decreased cellular cholesterol synthesis and CE mass by up to 96% (P < 0.001) and 52% (P < 0.001), respectively. However, in contrast to atorvastatin, simvastatin had no effect on apoB secretion. To characterize the reduction in apoB secretion by atorvastatin (10 µM), pulse-chase experiments were performed and the kinetic data were analyzed by multicompartmental modeling using SAAM II. Atorvastatin had no affect on the synthesis of apoB, however, apoB secretion into the media was decreased by 44% (P = 0.048). Intracellular apoB degradation increased proportionately (P = 0.048). Simvastatin (10 µM) treatment did not significantly alter either the secretion or intracellular degradation of apoB, relative to control. The kinetics of apoB degradation were best described by a rapidly and a slowly turning over degradation compartment. The effect of atorvastatin on apoB degradation was largely confined to the rapid compartment. Neither inhibitor affected apoB mRNA concentrations, however, both significantly increased LDL receptor and HMG-CoA reductase mRNA levels. Atorvastatin treatment also decreased the mRNA for the microsomal triglyceride transfer protein (MTP) by 22% (P < 0.02).

These results show that atorvastatin decreases apoB secretion, by a mechanism that results in an enhanced intracellular degradation of apoB.—Wilcox, L. J., P. H. R. Barrett, and M. W. Huff. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J. Lipid Res. 1999. 40: 1078–1089.

Supplementary key words: HMG-CoA reductase inhibitor, apoB, HepG2 cells, cholesterol synthesis, atorvastatin, simvastatin

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. K. Hihi, M.-C. Beauchamp, R. Branicky, A. Desjardins, I. Casanova, M.-P. Guimond, M. Carroll, M. Ethier, I. Kianicka, K. McBride, et al. Evolutionary conservation of drug action on lipoprotein metabolism-related targets J. Lipid Res., January 1, 2008; 49(1): 74 - 83. [Abstract] [Full Text] [PDF]

				R. Ramakrishnan Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments J. Lipid Res., December 1, 2006; 47(12): 2738 - 2753. [Abstract] [Full Text] [PDF]

				K. Bach-Ngohou, K. Ouguerram, R. Frenais, P. Maugere, B. Ripolles-Piquer, Y. Zair, M. Krempf, and J. M. Bard Influence of Atorvastatin on Apolipoprotein E and AI Kinetics in Patients with Type 2 Diabetes J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 363 - 369. [Abstract] [Full Text] [PDF]

				S.-K. Kang, T.-W. Chung, J.-Y. Lee, Y.-C. Lee, R. E. Morton, and C.-H. Kim The Hepatitis B Virus X Protein Inhibits Secretion of Apolipoprotein B by Enhancing the Expression of N-Acetylglucosaminyltransferase III J. Biol. Chem., July 2, 2004; 279(27): 28106 - 28112. [Abstract] [Full Text] [PDF]

				K. Ouguerram, T. Magot, Y. Zair, J. S. Marchini, B. Charbonnel, H. Laouenan, and M. Krempf Effect of Atorvastatin on Apolipoprotein B100 Containing Lipoprotein Metabolism in Type-2 Diabetes J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 332 - 337. [Abstract] [Full Text] [PDF]

				Y. Higashi, H. Itabe, H. Fukase, M. Mori, Y. Fujimoto, and T. Takano Transmembrane Lipid Transfer Is Crucial for Providing Neutral Lipids during Very Low Density Lipoprotein Assembly in Endoplasmic Reticulum J. Biol. Chem., June 6, 2003; 278(24): 21450 - 21458. [Abstract] [Full Text] [PDF]

				K. G. Parhofer, E. Laubach, and P. H. R. Barrett Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients J. Lipid Res., June 1, 2003; 44(6): 1192 - 1198. [Abstract] [Full Text] [PDF]

				N. M. Borradaile, L. E. de Dreu, P. H. R. Barrett, and M. W. Huff Inhibition of hepatocyte apoB secretion by naringenin: enhanced rapid intracellular degradation independent of reduced microsomal cholesteryl esters J. Lipid Res., September 1, 2002; 43(9): 1544 - 1554. [Abstract] [Full Text] [PDF]

				T. Nishimaki-Mogami, Z. Yao, and K. Fujimori Inhibition of phosphatidylcholine synthesis via the phosphatidylethanolamine methylation pathway impairs incorporation of bulk lipids into VLDL in cultured rat hepatocytes J. Lipid Res., July 1, 2002; 43(7): 1035 - 1045. [Abstract] [Full Text] [PDF]

				D. C. Chan, G. F. Watts, P. H. R. Barrett, T. A. Mori, L. J. Beilin, and T. G. Redgrave Mechanism of Action of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor on Apolipoprotein B-100 Kinetics in Visceral Obesity J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2283 - 2289. [Abstract] [Full Text] [PDF]

				L. J. Wilcox, N. M. Borradaile, L. E. de Dreu, and M. W. Huff Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP J. Lipid Res., May 1, 2001; 42(5): 725 - 734. [Abstract] [Full Text]

				K. G. Parhofer, P. H. R. Barrett, and P. Schwandt Atorvastatin Improves Postprandial Lipoprotein Metabolism in Normolipidemic Subjects J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4224 - 4230. [Abstract] [Full Text]

				J. R. Burnett, L. J. Wilcox, D. E. Telford, S. J. Kleinstiver, P. H. R. Barrett, R. S. Newton, and M. W. Huff The Magnitude of Decrease in Hepatic Very Low Density Lipoprotein Apolipoprotein B Secretion Is Determined by the Extent of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition in Miniature Pigs Endocrinology, November 1, 1999; 140(11): 5293 - 5302. [Abstract] [Full Text]